ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,509.01
0.62%
US Tech 100
19,493.20
0.07%
Dow Jones
39,331.85
0.41%
Brent Oil
86.10
-0.40%
Bitcoin
60,116.27
-3.08%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Cryptocurrencies
  4. COIN
  5. (Cryptocurrency:TRITEUR)

  6. (Cryptocurrency:TRITEUR) News

TRITEUR

(TRITEUR)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
07/03/20241:00AMBusiness Wireシカモア・ツリー・キャピタル・パートナーズ「Best US Boutique CLO Manager Award」を受賞
07/03/20241:00AMGlobeNewswire Inc.Start of Day Message
07/03/20241:00AMBusiness WireElliptic Labs Signs Expansion Contract with Commercial Segment of PC Customer
07/03/20241:00AMBusiness WireBenevolentAI: Leadership Team Change
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDBIT:SANFSanofi
07/03/20241:00AMGlobeNewswire Inc.Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneTG:SNWSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDBIT:1SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneBIT:SANFSanofi
07/03/20241:00AMGlobeNewswire Inc.Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenneBIT:1SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDEU:SANSanofi
07/03/20241:00AMGlobeNewswire Inc.Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDTG:SNWSanofi
07/03/20241:00AMPR Newswire (US)iTRAK 5750 Intelligent Track System from Rockwell Automation Enables Faster, More Flexible Motion Across Heavier PayloadsNYSE:ROKRockwell Automation Inc
07/03/202412:28AMAlliance NewsAlliance NewsGLOBAL BRIEFING: Europe called up as Powell revives rate cut hopes
07/03/202412:19AMGlobeNewswire Inc.Yantai Exhibition Celebrates 27th Anniversary of Hong Kong's Return to Motherland
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CLAYUChavant Capital Acquisition Corporation
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBSENeuBase Therapeutics Inc
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBSENeuBase Therapeutics Inc
07/03/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ROCAUROC Energy Acquisition Corporation
07/03/202412:15AMPR Newswire (US)/C O R R E C T I O N -- Wormington & Bollinger/
07/03/202412:10AMPR Newswire (US)Persistent Acquires Starfish Associates, Strengthening its Position in AI-powered Contact Center and Unified Communications
07/03/202412:01AMPR Newswire (US)HOME AFFORDABILITY GETS TOUGHER DURING SECOND QUARTER ACROSS U.S. AS PRICES SHOOT BACK UP
07/03/202412:00AMPR Newswire (US)New Novel Illustrates What Loss Of Liberty Could Look Like
07/03/202412:00AMPR Newswire (US)Summer is High Time to Visit the Tennessee River Valley in Georgia's Coolest Place
07/03/202412:00AMPR Newswire (US)Be The Best You Can Be, Take Advantage Of The Opportunities Presented, And Never Give Up
07/03/202412:00AMPR Newswire (US)Fans Can Return to Aeramor As The Heavenly Places Series Continues With Book Two
07/03/202412:00AMPR Newswire (US)God Is Ready And Willing To Walk With His Children Through Their Difficulties
07/03/202412:00AMPR Newswire (US)While Many Around America Are Acting Out Of Hate, One Author Believes The Solution Is Love

Your Recent History

NASDAQ
TSLA
Tesla
USOTC
NNAX
New Momentum (PK)
USOTC
ASKH
Astika (PK)
USOTC
CNNA
Cann American (CE)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
PHIL
PHI (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
TSOI
Therapeutic Solutions (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
HMBL
HUMBL (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
AXXA
Exxe (PK)
USOTC
BLLB
Bell Buckle (PK)
USOTC
RXMD
Progressive Care (QB)
USOTC
GGSM
Gold and GemStone Mining (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved